Akero Therapeutics Inc
Change company Symbol lookup
Select an option...
AKRO Akero Therapeutics Inc
PG Procter & Gamble Co
AFRM Affirm Holdings Inc
RMI RiverNorth Opportunistic Municipal Income Fund, Inc.
LBAI Lakeland Bancorp Inc
BREA Brera Holdings PLC
GVYB Golden Valley Bank
DHC Diversified Healthcare Trust

Health Care : Biotechnology | Small Cap Growth
Company profile

Akero Therapeutics, Inc. is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases. The Company is engaged to treat non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. The Company’s lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. EFX is being evaluated in two Phase 2b clinical trials in patients with biopsy-confirmed NASH: a long-term follow-up period for the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), for which it reported results after 24 weeks of treatment, and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). Its EFX program focused on patients with cirrhotic NASH (F4, compensated), in Phase 2b clinical trial.

Day's Change
-1.31 (-2.45%)
B/A Size
Day's High
Day's Low
(Below Average)

Today's volume of 243,142 shares is on pace to be lower than AKRO's 10-day average volume of 673,357 shares.


Upcoming Events

AKRO's fiscal year ends in December
There are no upcoming events for AKRO

Past Earnings

This page reports .
DateEvent descriptionEarnings per
share actual
estimate range
Previous year's
May 15, 2023Q1 2023 Earnings Release-$0.55-$0.80 to -$0.58-$0.74
March 17, 2023Q4 2022 Earnings Release-$0.49-$0.89 to -$0.67-$0.93
November 4, 2022Q3 2022 Earnings Release-$0.92-$0.81 to -$0.64-$0.70
August 4, 2022Q2 2022 Earnings Release-$0.77-$1.04 to -$0.72-$0.83

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

, , , Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.